Research programme: telomerase inhibitors - Antisoma
Alternative Names: AS 1410; BRACO 19; Telomere targeting agentsLatest Information Update: 15 Mar 2010
At a glance
- Originator Cancer Research UK
- Developer Antisoma; Cancer Research UK
- Class
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Dec 2005 Antisoma has decided not to advance AS 1410 to clinical development due to unacceptable toxicity
- 03 Jun 2005 Antisoma has signed an agreement with Heraeus so that the latter company will provide supplies of AS 1410 for clinical trials
- 05 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section ,